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In the present study, a series of pyrazolines 2a-c, isoxazoline 5, pyrimidines 3aʹ-cʹ and benzoazepines 4aʹʹ-cʹʹ have been 
prepared from the cyclization reactions of biphenyl chalcone 1 with appropriate binucleophilic reagents. The chalcone 1 has 
been obtained by using the Claisen-Schmidt condensation reaction of 2-hydroxyacetophenone with biphenyl-4-
carboxaldehyde in EtOH/NaOH medium. The structural interpretations of the chalcone 1 and final heterocycles have been 
fully ascribed on the basis of their different spectroscopic parameters such as IR, 1H and 13C NMR, and ESI-MS. The 
in vitro antimicrobial evaluation of these heterocycles have also been carried out by using serial tube dilution technique 
against the selected number of bacterial and fungal strains and most of the studied products proved to be the potent 
antimicrobial agents. The newly prepared pyrazolines and isoxazoline exhibit noticeable antimicrobial properties. 
Keywords: Chalcone, pyrazoline, isoxazoline, pyrimidine, benzodiazepine, benzoxazepine, benzothiazepine, antimicrobial 
Heterocyclic chemistry has been one of the significant 
branch of organic syntheses which has provided the 
useful thrust area to the synthetic as well as analytical 
chemists for rapid development in the different fields 
such as medicinal, analytical and pharmaceutical 
industries1,2. These compounds are challenging 
models for the diversity of bioactive products which 
are considered as the precursor vehicles for the 
preparations of the many chemically and biologically 
useful scaffolds3. The most of known products  
in the nature are heterocyclic in character and their 
numbers have been expanding continuously due to 
their versatile applications in the industrial as well as 
biological systems4. The nitrogen, sulfur and oxygen 
have been widely exploited as the hetero atoms in 
these compounds5,6. The significant aspect of 
heterocycles is their ability for incorporating the 
functional groups on their rings as the substituents. 
The modern day’s development of research works in 
the field of synthetic chemistry have become the key 
challenge for the researchers in order to investigate 
novel and efficient protocols for the preparations of 
exotic heterocyclic system. Thus, these days major 
emphasis has been directed upon the designing, 
constructions and recognitions of the biologically 
promising new heterocycles7-11. 
The molecules bearing two completely delocalized 
aromatic rings joined through the α,β-unsaturated 
carbonyl group are named as chalcones that are 
widely identified as the significant building block in 
the synthesis of many biologically significant 
compounds, polymers as well as in potential drug 
target molecules12-19. Chalcones are the polyphenolic 
natural products that are found to be present in 
vegetables, fruits, spices, tea and soya based 
foodstuffs20,21. Recently, molecular docking studies 
have revealed that chalcone derivatives are also being 
utilized as the potential epidermal growth factor 
receptor inhibitors22-25. 
Pyrazoles are the most privileged five membered 
heterocyclic scaffolds having two nitrogen atoms at 
adjoining locations in the ring and their partially 
reduced structures are named as pyrazolines26-28. The 
immense applications of this moiety in the biological 
field have increased the enormous curiosity among 
the chemists to investigate their structural frame 
work29,30. The pyrazole moiety has been found to exist 
in various well-established pharmaceutical drugs such 
as lonazolac 1 (anti-inflammatory), rimonabant 2 
(anti-obesity), difenamizole 3 (analgesic), CDPPB 4 
(antipsychotic) and betazole 5 (H2-receptor agonist)31-35 
(Figure 1). The existence of this scaffold in many 
bioactive products and broad spectrum of 
chemotherapeutic products have led to their great role 
in different areas like medicine, agriculture and 
technology36. Pyrazoles and their derivatives have 
been utilized as the antimicrobial37, anticancer38, anti-
tubercular39, anticonvulsant40, antioxidants41, anti-
depressants42 and antiviral agents43. 
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Isoxazoles are the decisive set of five membered 
heterocycles in which oxygen and nitrogen are 
situated at the contiguous positions whereas their 
dihydro forms are described as isoxazolines44-46. 
These substrates have acquired considerable 
importance due to their valuable agrochemical and 
pharmacological properties47-53. Isoxazole moiety is 
also found to be present in some of the indispensable 
drugs like leflunomide 6, sulfafurazole 7, valdecoxib 
8 and oxacillin 954,55 (Figure 2). Isoxathion, isouron 
and isoxaben are the examples of degradable 
pesticides containing substituted isoxazoles in their 
structural skeleton56,57. 
Pyrimidines are belonging to diazines family 
containing two nitrogen atoms at 1,3-positions in the 
six membered aromatic rings58. The synthetic studies 
of these heterocycles have been extensively exploited 
owing to their presence in a large variety of drugs, co-
enzymes, natural products, nucleic acids and 
vitamins59-68. The top marketing pharmaceutical 
products such as zidovudine 10, floxuridine 11, 
minoxidil 12, pyrimethamine 13, flucytosine 14, 
lamivudine 15 and lopinavir 16 are consisting of 
pyrimidine ring systems69 (Figure 3). This heterocycle 
is also found to be present in some useful derivatives 
of barbituric acid like pentothal, veronal and luminal 
which are used as the potential therapeutic agents70-73. 
The studies of seven membered heterocycles 
azepines and their polycyclic derivatives have 
attracted much attention in the past decades due to 
their wide spectrum of industrial and biological 
significances74,75. 1,2-Oxazepines and 1,2-diazepines 
are known to act as the potential opioid analgesics and 
antihypertensive agent respectively76,77. The diazepam 
17 have been used as the antianxiety drug and 
quazepam 18 as anticonvulsant78 (Figure 4). 1,5-
Benzothiazepines are found to be related with 
vasodilator, Ca-antagonist and platelet aggregation 
inhibitor actions79. 
Presently in the field of synthetic and medicinal 
chemistry, the foremost point is to investigate the 
synthesis of novel heterocyclics with promising 
bioactivities. Therefore, these days major researches 
have been directed upon the development of 
proficient methods to obtain the potential heterocyclic 
products with privileged structures80-83. 
The presence of two electrophilic reactive centers 
in the structural unit of chalcone makes them highly 
versatile and attractive synthons for the preparations 
of the variety of biologically potent varied ring 
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heterocycles systems (five/six/seven membered) 
through their cyclization reactions with suitable bi-
nucleophilic reagents84-89. 
Encouraged by the above literature studies and on 
the basis of our preceding efforts on synthesis of new 
heterocyclic products90-94, the proposed researches 
have been focused upon the chemical transformations 
of chalcone 1 with variety of binucleophilic reagents 
in order to acquire new pyrazoline, isoxazoline, 
pyrimidine, benzodiazepine, benzoxazepine and 
benzothiazepine derivatives. The main interest behind 
the preparations of these heterocycles was to explore 
the effect of the ring size of heterocyclic moiety 
(five/six/seven membered) upon their formations and 
the antimicrobial properties. 
 
Results and Discussion 
The heterocycles 2(a-c), 3(aʹ-cʹ), 4(aʹʹ-cʹʹ) and 5 
have been prepared conveniently in the laboratory  
by using the cyclocondensation reactions of  
biphenyl chalcone 1 with appropriate ring closure  
reagents (phenyl hydrazine, hydrazine hydrate, 
thiosemicarbazide, hydroxylamine hydrochloride, 
thiourea, urea, guanidine hydrochloride, o-pheny-
lenediamine, 2-aminophenol and 2-aminothiophenol) 
under the refluxing conditions. The chalcone 1 was 
attained from the Claisen-Schmidt condensation 
reaction of 2-hydroxyacetophenone and biphenyl-4-
carboxaldehyde in EtOH/NaOH medium. The 
structures of the chalcone 1 and final heterocycles 
have been completely attributed on the account of 
their various spectroscopic strategies (IR, 1H NMR, 
13C NMR, and ESI-MS) and the purity of these 
products was assured from their TLC and elemental 
analysis results. The pathway for the synthesis of 
chalcone 1 and target compounds 2(a-c), 3(aʹ-cʹ), 
4(aʹʹ-cʹʹ) and 5 have been outlined in Scheme I. 
IR spectrum of chalcone 1 demonstrated the  
three apparent bands at 3372 (O-H), 1652 (C=O) and 
1574 cm−1 (C=C). In its 1H NMR spectrum (400 MHz, 
DMSO-d6), the emergence of D2O exchangeable 
broad singlet positioned at δ 9.68 defines the presence 
of the OH group proton. The double bond hydrogens 
H-3 and H-2 were found to be resonating in the form 
of a doublet each at δ 7.81 and 7.76 respectively and 
the coupling value of J2,3=15.6 Hz established their 
trans correlation. The thirteen protons belonging to 
C1-phenyl (H-3ʹ, 4ʹ, 5ʹ, 6ʹ) and C3-biphenyl rings  
(H-2ʹʹ, 3ʹʹ, 5ʹʹ, 6ʹʹ, H-2ʹʹʹ, 3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ, 6ʹʹʹ) revealed the 
signals in the aromatic region at the appropriate 
places (vide Experimental Section). 
13C NMR spectrum (100 MHz, DMSO-d6) was 
further very supportive for illustrating its carbon 
scaffold. The appearance of most downfield 
resonance at δ 189.03 may be ascribed to the carbonyl 
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group whereas carbon atoms of the olefinic bond C-3 
and C-2 exhibited their suitable signals at δ 143.18 
and 119.26 respectively. The other perceptible signal 
was displayed by the C-2ʹ carbon at δ 157.68 due to 
its direct connection with oxygen atom of the 
hydroxyl group. The remaining aromatic carbon 
atoms related to C1-phenyl and C3-biphenyl rings 
were found to be positioned at the expected δ values 
(vide Experimental Section). 
IR spectra of heterocycles 2(a-c), 3(aʹ-cʹ), 4(aʹʹ-cʹʹ) 
and 5 showed the broad bands at 3500-3214 cm−1 
which ascribed the presence of O-H functional group 
in their structures. The existence of OH substituent in 
these compounds was again corroborated from their 
1H NMR spectra (400 MHz, CDCl3/ DMSO-d6) by the 
manifestation of D2O exchangeable broad singlets at δ 
9.86-7.27. 
IR spectra of 2(a-c) showed the substantial 
absorptions at 1596-1590 cm−1 owing to the C=N 
stretching frequency of the pyrazoline ring. The 
appearance of intense absorption at 3458 cm−1 
suggested the presence of N-H group in compound 
2b. Product 2c exhibited three noticeable bands at 
3447, 3419 (N-H) and 1199 (C=S) cm−1. In the 
1H NMR (400 MHz, CDCl3/DMSO-d6) spectra of 
pyrazolines 2(a-c), the imperative aspect was the 
three well distinctive doublet of doublets situated at  
δ 6.00-5.28, 3.97-3.80 and 3.15-3.12 that could be 
easily attributed to pyrazoline ring protons Hx, HM 
and HA respectively. The presence of chiral center at 
C-5 carbon of the pyrazoline ring is found to be 
responsible for the AMX splitting pattern of these 
three protons and the stereochemical interactions 
among these protons was elucidated on the basis of 
their mutual coupling constants. The coupling value 
of JXA=6.9-3.3 Hz represent the trans disposition of 
HX and HA whereas JXM=12.1-11.5 Hz depicts the cis 
orientation of HX and HM with respect to each other. 
The coupling constant of JMA=18.0-17.2 Hz proves 
that HM and HA are geminally placed at C-4. In 
compound 2c, the presence of two broad singlets 
integrating for one hydrogen each at δ 8.12 and 7.93 
 
 
Scheme I — Synthesis of pyrazolines 2a-c, pyrimidines 3aʹ-cʹ, benzoazepines 4aʹʹ-cʹʹ and isoxazoline 5 
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correspond to the two NH2 group protons. The 
occurrence of broad singlet at δ 8.99 was easily 
assignable to NH group proton in compound 2b. The 
C3-phenyl and C5-biphenyl rings protons produced 
their appropriate signals in the aromatic region  
(vide Experimental Section).13C NMR (100 MHz, 
DMSO-d6) spectra of 2(a-c) were quite influential to 
authenticate their carbon framework which displayed 
noticeable signals at δ 158.31-157.46 due to C-2ʹʹ in 
2a and C-2ʹ in 2b and 2c. The appearance of three 
appropriate resonances centered at δ 155.15-147.31 
(C-3), 63.23-62.54 (C-5) and 42.94-42.38 (C-4) 
confirmed the formation of pyrazoline rings. The 
location of downfield signal at δ 175.99 was able to 
validate the presence of C=S group in product 2c. The 
remaining aromatic rings carbon atoms (C3-phenyl 
and C5-biphenyl) were found to be located at the 
appropriate δ values (vide Experimental Section).  
IR spectra of pyrimidines 3(aʹ-cʹ) showed the 
major absorptions at 3379, 3305 (N-H), 3378 (O-H) 
and 2644 cm−1 (S-H). The absence of C=O functional 
group band represented its involvement in the 
chemical transformations and here noticeable 
absorptions were observed at 1597-1590 cm−1 due to 
the C=N moiety of the diazine ring. 1H NMR (400 
MHz, CDCl3/DMSO-d6) spectra of 3(aʹ-cʹ) showed 
the characteristic signals in the form of appropriate 
singlet at δ 8.38-7.65 that could be easily assigned to 
the H-5 of pyrimidine ring along with D2O 
exchangeable resonances of C2-NH2, C2-SH and  
C2-OH group protons at δ 8.40, 13.68 and 9.83 
respectively. The remaining aromatic ring protons 
(C4-phenyl and C6-biphenyl) were centered at the 
suitable δ values (vide Experimental Section). 
13C NMR (100MHz, DMSO-d6) spectra of 3(aʹ-cʹ) 
exhibited the resonances of pyrimidine ring carbon 
atoms at δ 178.60-165.18 (C-2), 165.76-163.41 (C-4), 
163.18-160.96 (C-6) and 109.98-106.96 (C-5). The 
C4-phenyl and C6-biphenyl rings carbon atoms were 
situated in the aromatic regions at the appropriate δ 
values (vide Experimental Section).  
IR spectra of seven membered heterocycles 4(aʹʹ-cʹʹ), 
showed the intense band at 1600-1589 cm−1 that 
suggested the presence of C=N group in their 
structures. The appearance of perceptible absorption 
at 3480 cm−1 affirmed the presence of N-H group  
in benzodiazepine 4aʹʹ. In the 1H NMR spectra  
(400 MHz, CDCl3/DMSO-d6) of 4aʹʹ, presence of NH 
proton was further established from the appearance of 
a broad singlet at δ 8.71. The formation of the 
heterocycles 4(aʹʹ-cʹʹ) were confirmed from the 
appearance of suitable singlets at δ 6.33-5.25 which 
may be resulted by the H-3 proton of the seven 
membered ring. The remaining hydrogens were found 
to be resonating in the aromatic region at the suitable 
δ values (vide Experimental Section). In the 13C NMR 
(100 MHz, DMSO-d6) spectra of 4(aʹʹ-cʹʹ), the 
heterocyclic ring five carbon atoms C-2, C-6, C-11, 
C-4 and C-3 were easily resonating at δ 164.68-
164.15, 152.43-150.01, 145.08-143.35, 143.88-142.17 
and 99.15-90.37 respectively. The carbon atoms of 
the aromatic rings (C2-phenyl and C4-biphenyl) 
produced their signals at their appropriate places (vide 
Experimental Section). 
In the IR spectrum of of isoxazoline 5, a band was 
observed at 1600 cm−1 that proved the existence of 
C=N
 
moiety in this molecule. Its 1H NMR spectrum 
(400 MHz, CDCl3) was very accessible to elucidate 
its structure. Three well splitted doublet of doublets 
situated at δ 5.62, 3.75 and 3.18 were easily allocated 
to isoxazoline ring protons HX, HM and HA 
respectively that corroborated the presence of AMX 
splitting system in isoxazoline. The coupling values 
confirmed the stereochemical correlation among these 
hydrogens. The vicinal coupling value of 11.5 Hz 
between the HX and HM revealed their cis relationship 
while coupling constant of 4.6 Hz between HX and HA 
suggested the trans association between these protons. 
The coupling value of 17.2 Hz demonstrated the 
geminal location of HA and HM at C-4. Rest of the 
protons belonging to C3-phenyl and C5-biphenyl rings 
could generate their suitable signals in the aromatic 
region (vide Experimental Section). In the 13C NMR 
(100 MHz, DMSO-d6), the isoxazolidine ring carbon 
atoms C-3, C-5 and C-4 furnished their appropriate 
signals at δ 154.25, 60.13 and 42.05 respectively. The 
recognizable signals present at δ 157.52 confirmed the 
presence of C-2ʹ because of its direct bonding with 
oxygen atom. The C3-phenyl and C5-biphenyl ring 
carbon atoms were found to be situated in the 
aromatic regions (vide Experimental Section). 
The structural features of the newly prepared 
heterocycles 2(a-c), 3(aʹ-cʹ), 4(aʹʹ-cʹʹ) and 5 were 
further corroborated on the basis of their ESI-MS 
spectral data (vide Experimental Section). 
 
Antimicrobial Activity of 2(a-c), 3(aʹ-cʹ), 4(aʹʹ-cʹʹ) 
and 5 
The in vitro antimicrobial assessment of all the 
newly synthesized heterocycles 2(a-c), 3(aʹ-cʹ), 4(aʹʹ-
cʹʹ) and 5 was implemented with the help of serial 
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tube dilution process95 against the seven bacterial 
(Escherichia coli, Pseudomonas aeruginosa, Klubsellia 
pneumonia, Bacillius subtilis, Staphylococcus aureus, 
Pseudomonas fluorescens and Streptoccus pyrogens) 
and five Fungal pathogens (Aspergillus sclerotum, 
Aspergillus janus, Penicillium glabrum, Aspergillus 
niger and Fusarium oxysporum). The MIC 
estimations of these heterocycles against the above 
depicted microorganisms was carried out by making 
varied concentrations of 128, 64, 32, 16, 8 and 
4 µg/mL in DMSO that was served in the form  
of negative control. The smallest concentration of the 
heterocycles essential to suppress the noticeable 
production of a microorganism after incubation  
was measured as the minimum inhibitory 
concentration. Standard antimicrobial drugs such as 
Amoxicillin (for antibacterial) and Fluconazole  
(for antifungal) were used to contrast the MIC 
outcome of all the tested products. These drugs 
provided as the positive control. Nutrient broth and 
malt extract medium supplied as the nourishment to 
bacteria and fungi respectively. The accessibility of 
the concerned compounds on the microbial growth 
was viewed from the emergence of turbidity within 
the test tubes after 24 h of incubation at 37°C for 
bacterial cultures and 72 h of incubation at 28°C for 
fungal species. The minimum inhibitory concentration 
(MIC) results of 2(a-c), 3(aʹ-cʹ), 4(aʹʹ-cʹʹ) and 5 have 
been expressed in Table I. 
It is apparent from Table I that heterocycle 2a 
provided potent behaviours against E. coli, S. aureus 
and F. oxysporum at the MIC of 8 µg/mL  
whereas compound 2b was found to be highly active 
(MIC-8 µg/mL) against K. pneumonia, A. janus and 
A. sclerotiorum. The products 2c suppressed the 
growth of P. fluorescens, S. pyogenes, F. oxysporum 
at the MIC of 8 µg/mL. The compound 5 could afford 
appreciable activity (MIC-8 µg/mL) against S. aureus, 
P. glabrum and A. niger. Product 3aʹ exhibited MIC 
of 8 µg/mL against P. Aeruginosa. The heterocycles 
3bʹ and 3cʹ demonstrated recognizable results against 
E. coli, A. janus, K. pneumonia and S. pyogenes 
respectively at the MIC of 8 µg/mL. Compounds 4aʹʹ 
and 4bʹʹ showed effectual response against  
P. fluorescens and P. aeruginosa respectively at the 
similar MIC values whereas product 4cʹʹ attained 
moderate inhibitory activitiy against P. fluorescens 
and F. oxysporum.  
It is also comprehensible from these results that 
majority of the prepared heterocycles revealed modest 
level of actions against the tested microorganisms 
(MIC-16 µg/mL). 
The above given antimicrobial results emphasized 
that pyrazolines 2(a-c) and isoxazoline 5 exhibited 
promising antibacterial and antifungal properties as 
compared to pyrimidine 3(aʹ-cʹ) and benzoazepine 
4(aʹʹ-cʹʹ) derivatives. 
 
Experimental Section 
 
Materials and methods 
The entire reagents and solvents needed for  
the present investigations were procured from  
E-Merck, S. D. Fine-Chem. Limited, Sigma-Aldrich 
Corporations and open capillary tube equipment was 
used for evaluating the melting points of the newly 
prepared heterocycles. TLC plates coated with Silica-
Gel G were utilized to scrutinize the progress of given 
reactions and purity of products was assessed by 
taking the hexane and ethyl acetate (1:1) as the mobile 
Table I — In vitro MIC (µg/mL) data of 2a-c, 3aʹ-cʹ, 4aʹʹ-cʹʹ and 5 
Compd Gram (-ve) bacteria Gram (+ve) bacteria Fungi 
E. 
coli 
K. 
pneumonia 
P. 
Aeruginosa 
P. 
Fluorescens 
S. 
aureus 
B. 
subtilis 
S. 
Pyogenes 
A. 
Janus 
P. 
Glabrum 
A. 
Niger 
F. 
oxysporum 
A. 
sclerotiorum 
2a 8 32 16 32 8 32 16 32 32 32 8 32 
2b 16 8 32 16 32 16 32 8 16 16 32 8 
2c 32 16 32 8 32 32 8 16 32 32 8 16 
3aʹ 32 32 8 32 16 32 32 32 16 32 32 16 
3bʹ 8 32 32 16 32 32 32 8 32 32 16 32 
3cʹ 32 8 32 32 32 32 8 32 16 32 32 32 
4aʹʹ 32 32 32 8 32 32 32 32 32 32 16 32 
4bʹʹ 32 32 8 32 32 32 16 32 32 16 32 32 
4cʹʹ 32 32 32 16 32 32 32 32 32 32 16 32 
5 32 16 16 32 8 32 16 32 8 8 32 16 
Amoxicillin 4 4 4 4 2 2 4 − − − − − 
Fluconazole − − − − − − − 2 2 2 2 2 
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phase and spots were observed by placing these plates 
in the iodine chamber. Perkin XEVO G2-XS QTOF 
and Elmer FT-IR spectrophotometers have been 
employed for recording the ESI-MS and Infrared 
spectra respectively. 1H and 13C NMR spectra  
were scanned on Bruker Advance-II Spectrometer 
operating at 400 MHz and 100 MHz respectively by 
taking suitable deuterated solvents (DMSO-d6/CDCl3) 
as well as tetramethylsilane (TMS) in the form of 
internal standard and chemical shifts are reported in δ 
(ppm) values. 
 
Synthesis of (2E)-3-(biphenyl-4-yl)-1-(2-hydroxy 
phenyl)prop-2-en-1-one, 1 
A mixture of 2-hydroxyacetophenone (3.0 g, 0.022 
mol), bipheny-4-carboxaldehyde (4.0 g, 0.022 mol), 
dry ethanol (25.0 mL) and sodium hydroxide (3.5 g, 
0.087 mol) was intensely stirred at 0ºC for 5 h on a 
magnetic stirrer. Upon the execution of the reaction, 
the mixture was transformed into a reddish mass that 
was covered and placed in a refrigerator for 12 h. 
After that the resulting reaction mixture was poured 
slowly into the crushed ice with constant shaking and 
its neutralization was carried out with dilute HCl to 
furnish a light yellow solid which was crystallized by 
taking the equimolar quantity of MeOH:CHCl3 to 
realize a pure compound 1. 
1: Yield 5.5 g (85%), light yellow needles, m.p. 
142-144°C. IR (KBr): 3372 (O-H), 3030 (aromatic C-H), 
1652 (C=O), 1574 (C=C) and 1558, 1519, 1486,  
1451 cm−1 (aromatic C=C); 1H NMR (400 MHz, 
DMSO-d6): δ 9.68 (1H, brs, OH), 7.90 (2H, d, Jo = 8.3 
Hz, H-2ʹʹ, 6ʹʹ), 7.81 (1H, d, Jtrans = 15.6 Hz, H-3), 7.76 
(1H, d, Jtrans = 15.6 Hz, H-2), 7.71 (4H, m, H-3ʹʹ, 5ʹʹ, 
2ʹʹʹ, 6ʹʹʹ), 7.59 (1H, d, Jo = 7.8 Hz, H-6ʹ), 7.46 (3H, m, 
H-3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ), 7.39 (1H, d, Jo = 7.8 Hz, H-5ʹ), 7.34 
(1H, d, Jo = 7.1 Hz, H-3ʹ), 7.04 (1H, dd, Jm,o = 2.5, 8.0 
Hz, H-4ʹ) ); 13C NMR (100 MHz, DMSO-d6): δ 
189.03 (C=O), 157.68 (C-2ʹ), 143.18 (C-3), 142.17 
(C-1ʹʹ), 139.28 (C-1ʹ), 139.02 (C-4ʹʹ), 133.60 (C-1ʹʹʹ), 
129.43 (C-2ʹʹ, 6ʹʹ), 129.05 (C-3ʹʹ, 5ʹʹ), 128.72 (C-2ʹʹʹ, 
6ʹʹʹ), 127.67 (C-3ʹʹʹ, 5ʹʹʹ), 126.97 (C-4ʹʹʹ), 126.53  
(C-6ʹ), 121.86 (C-5ʹ), 120.06 (C-3ʹ), 119.26 (C-2), 
114.68 (C-4ʹ); ESI-MS: m/z 301 (M+1, 100%), 300 
(M+, 20%). Anal. Calcd for C21H16O2: C, 83.98; H, 
5.37. Found: C, 84.31; H, 5.39%. 
 
Synthesis of (R)-2-(5-[1,1ʹ-biphenyl]-4-yl)-1-phenyl-
4,5-dihydro-1H-pyrazol-3-yl)phenol, 2a 
A suspension of chalcone 1 (1.0 g, 0.003 mol), 
phenyl hydrazine (0.4 g, 0.003 mol), KOH (0.3 g, 
0.006 mol) and dry EtOH (25.0 mL) was heated under 
reflux for 6 h. The accomplishment of reaction was 
analyzed with the help of TLC [hexane:ethyl acetate 
(9:1)]. The mixture was cooled at room temperature 
and solvent was evaporated under reduced pressure. 
The resulting mass was added gently into ice cold 
hydrochloric acid solution to afford the crude product 
which was filtered off, dried and recrystallized from 
methanol to obtain the pure pyrazoline 2a. 
2a: Yield 0.95 g (73%), light brown solid, m.p. 
148-150°C. IR (KBr): 3500 (O-H), 3077 (aromatic  
C-H), 2928 (aliphatic C-H) and 1596 cm−1 (C=N); 
1H NMR (400 MHz, CDCl3): δ 7.54 (4H, d, Jo = 7.2 
Hz, H-3ʹʹʹ, 5ʹʹʹ, 2ʹʹʹʹ, 6ʹʹʹʹ), 7.41 (2H, t, Jo = 7.3 Hz,  
H-5ʹʹ, 6ʹʹ), 7.36 (2H, d, Jo = 8.1 Hz, H-3ʹʹʹʹ, 5ʹʹʹʹ), 7.31 
(2H, d, Jo = 7.2 Hz H-2ʹʹʹ, 6ʹʹʹ), 7.27 (1H, brs, OH), 
7.18 (4H, m, H-3ʹ, 4ʹ, 5ʹ, 4ʹʹʹʹ), 7.09 (2H, d, Jo = 7.9 
Hz, H-3ʹʹ, 4ʹʹ), 6.80 (2H, d, Jo = 7.0 Hz H-2ʹ, 6ʹ), 5.28 
(1H, dd, JXA = 6.9 Hz, JXM = 11.6 Hz, HX), 3.80 (1H, 
dd, JMX = 11.6 Hz, JMA = 17.2 Hz, HM), 3.12 (1H, dd, 
JAX = 6.9 Hz, JAM = 17.2 Hz, HA); 13C NMR (100 
MHz, DMSO-d6): δ 157.46 (C-2ʹʹ), 147.31 (C-3), 
144.19 (C-1ʹ), 141.64 (C-1ʹʹʹ), 139.64 (C-4ʹʹʹ), 
139.25(C-1ʹʹʹʹ), 133.47 (C-1ʹʹ), 129.70 (C-2ʹʹʹ, 6ʹʹʹ), 
128.91 (C-3ʹʹʹ, 5ʹʹʹ), 128.88 (C-2ʹʹʹʹ, 6ʹʹʹʹ), 127.41  
(C-3ʹʹʹʹ, 5ʹʹʹʹ), 127.29 (C-3ʹ, 5ʹ), 126.56 (C-5ʹʹ), 126.47  
(C-4ʹʹʹʹ), 118.57 (C-4ʹ), 116.90 (C-6ʹʹ), 116.05 (C-2ʹ, 6ʹ), 
112.89 (C-4ʹʹ), 111.98 (C-3ʹʹ), 62.71 (C-5), 42.94  
(C-4); ESI-MS: m/z 392 (M+2, 27%), 391 (M+1, 
100%). Anal. Calcd for C27H22N2O: C, 83.05; H, 5.68; 
N, 7.17. Found: C, 83.38; H, 5.70; N, 7.20%. 
 
Synthesis of (R)-2-(5-[1,1ʹ-biphenyl]-4-yl)-4,5-
dihydro-1H-pyrazol-3-yl)phenol, 2b 
The reaction of compound 1 (1.0 g, 0.003 mol) 
with hydrazine hydrate (0.2 g, 0.003 mol) in the same 
way as illustrated above for 2a led to the generation 
of heterocyclic 2b. 
2b: Yield 0.75 g (75%), Off white solid, m.p.  
144-146°C. IR (KBr): 3458 (N-H), 3264 (O-H), 3054 
(aromatic C-H), 2920 (aliphatic C-H) and 1592 cm−1 
(C=N); 1H NMR (400 MHz, DMSO-d6): δ 9.48 (1H, 
brs, OH), 8.99 (1H, brs, NH), 7.69 (4H, t, Jo = 7.7 Hz, 
H‐2ʹʹʹ, 3ʹʹʹ, 5ʹʹʹ, 6ʹʹʹ), 7.47 (2H, t, Jo = 7.1 Hz, H-2ʹʹ, 6ʹʹ), 
7.41 (1H, t, Jo = 7.5 Hz, H-4ʹʹʹ), 7.34 (2H, m, H-3ʹʹ, 5ʹʹ), 
7.25 (3H, t, Jo = 8.0 Hz, H-4ʹ, 5ʹ, 6ʹ), 6.94 (1H, dd,  
Jm,o = 2.1, 8.1 Hz, H-3ʹ), 5.62 (1H, dd, JXA = 6.1 Hz, 
JXM = 12.1 Hz, H-X), 3.87 (1H, dd, JMX = 12.1 Hz,  
JMA = 17.9 Hz, H-M), 3.13 (1H, dd, JAX = 6.1 Hz,  
JAM = 17.9 Hz, H-A); 13C NMR (100 MHz, DMSO-d6): 
δ 158.31 (C-2ʹ), 154.26 (C-3), 143.20 (C-1ʹʹ), 140.64 
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(C-4ʹʹ), 138.44 (C-1ʹʹʹ), 133.01 (C-1ʹ), 130.87 (C-2ʹʹ, 
6ʹʹ), 128.24 (C-3ʹʹ, 5ʹʹ), 127.55 (C-4ʹʹʹ)126.28 (C-2ʹʹʹ, 
6ʹʹʹ), 126.08 (C-3ʹʹʹ, 5ʹʹʹ), 124.79 (C-5ʹ), 118.23 (C-6ʹ), 
116.77 (C-4ʹ), 112.81 (C-3ʹ), 63.23 (C-5), 42.62 (C-4); 
ESI-MS: m/z 337 (M+Na, 65%), 316 (M+2, 32%), 315 
(M+1, 15%). Anal. Calcd for C21H18N2O: C, 80.23; H, 
5.77; N, 8.91. Found: C, 80.55; H, 5.79; N, 8.87%. 
 
Synthesis of (R)-5-([1,1ʹ-biphenyl]-4-yl)-3-(2-
hydroxyphenyl)- 4,5-dihydro-1H-pyrazole-1-car 
bothioamide 2c 
The product 2c was prepared by treating 1 (1.0 g, 
0.003 mol) with thiosemicarbazide (0.2 g, 0.003 mol) 
using the similar protocol as suggested previously  
for 2a. 
2c: Yield 0.83 g (69%), light yellow solid, m.p. 
218-220°C. IR (KBr): 3447, 3419 (N-H), 3291 (O-H), 
3050 (aromatic C-H), 2924 (aliphatic C-H), 1590 
(C=N) and 1199 cm−1 (C=S); 1H NMR (400 MHz, 
DMSO-d6): δ 9.72 (1H, brs, OH), 8.12 (1H, brs, NHα), 
7.93 (1H, brs, NHβ), 7.68 (4H, t, Jo = 8.1 Hz, H-2ʹʹʹ, 
3ʹʹʹ, 5ʹʹʹ, 6ʹʹʹ), 7.49 (2H, t, Jo = 7.4 Hz, H-2ʹʹ, 6ʹʹ), 7.38 
(1H, t, Jo = 7.3 Hz, H-4ʹʹʹ), 7.32 (2H, m, H-3ʹʹ, 5ʹʹ), 
7.28 (3H, t, Jo = 8.7 Hz, H-4ʹ, 5ʹ, 6ʹ), 6.94 (1H, dd,  
Jm,o = 1.8, 8.7 Hz, H-3ʹ), 6.00 (1H, dd, JXA = 3.3 Hz, 
JXM = 11.5 Hz, H-X), 3.97 (1H, dd, JMX = 11.5  
Hz, JMA = 18.0 Hz, H-M), 3.15 (1H, dd, JAX =3.3 Hz, 
JAM = 18.0 Hz, H-A); 13C NMR (100 MHz, DMSO-d6): 
δ 175.99 (C=S), 157.48 (C-2ʹ), 155.15 (C-3), 142.15 
(C-1ʹʹ), 139.87 (C-4ʹʹ), 138.85 (C-1ʹʹʹ), 132.09 (C-1ʹ), 
129.71 (C-2ʹʹ, 6ʹʹ), 128.90 (C-3ʹʹ, 5ʹʹ), 127.33 (C-
4ʹʹʹ)126.87 (C-2ʹʹʹ, 6ʹʹʹ), 126.55 (C-3ʹʹʹ, 5ʹʹʹ), 125.92 (C-
5ʹ), 118.14 (C-6ʹ), 117.71 (C-4ʹ), 113.58 (C-3ʹ), 62.54 
(C-5), 42.38 (C-4); ESI-MS: m/z 374 (M+1, 25%), 
373 (M+, 100%). Anal. Calcd for C22H19N3OS: C, 
70.75; H, 5.13; N, 11.25; S, 8.58. Found: C, 70.46; H, 
5.15; N, 11.29; S, 8.61%. 
 
Synthesis of 2-(6-([1,1ʹ-biphenyl]-4-yl)-2-
mercaptopyrimidin-4-yl)phenol 3aʹ 
A mixture of compound 1 (1.0 g, 0.003 mol), 
thiourea (0.3 g, 0.003 mol) and KOH (0.3 g, 0.006 
mol) was dissolved in EtOH (25.0 mL) and allowed to 
reflux for 5 h. After the accomplishment of reaction 
(as examined through TLC), the entire mixture was 
poured on to crushed ice with continuous shaking to 
achieve a yellow substance which was filtered under 
suction, washed successively with water and dried. 
The resulting crude product was purified from  
its crystallization in MeOH to provide a pure  
product 3aʹ. 
3aʹ: Yield 0.8 g (67%), yellow solid, m.p. 94-96°C. 
IR (KBr): 3408 (O-H), 3027 (aromatic C-H), 2644  
(S-H) and 1590 cm−1 (C=N); 1H NMR (400 MHz, 
DMSO-d6): δ 13.68 (1H, brs, S-H), 9.86 (1H, brs,  
O-H), 8.38 (1H, s, H-5), 7.88 (2H, d, Jo = 8.0 Hz,  
H-2ʹʹ, 6ʹʹ), 7.74 (4H, m, H-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 7.41  
(6H, m, H-4ʹ, 5ʹ, 6ʹ, 3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ), 6.98 (1H, dd,  
Jm,o = 2.5, 7.2 Hz, H-3ʹ); 13C NMR (100 MHz, 
DMSO-d6): δ 178.60 (C-2), 165.76 (C-4), 163.18  
(C-6), 157.68 (C-2ʹ), 143.51 (C-1ʹʹ), 138.81 (C-4ʹʹ, 
1ʹʹʹ), 129.94 (C-1ʹ), 129.08 (C-2ʹʹ, 6ʹʹ), 128.93 (C-3ʹʹ, 
5ʹʹ), 128.31 (C-2ʹʹʹ, 6ʹʹʹ), 127.98 (C-3ʹʹʹ, 5ʹʹʹ), 126.94 
(C-5ʹ), 126.90 (C-4ʹʹʹ), 126.74 (C-6ʹ), 119.08 (C-4ʹ), 
114.74 (C-3ʹ), 109.98 (C-5); ESI-MS: m/z 379 
(M+Na, 49%), 357 (M+1, 63%), 356 (M+, 100%). 
Anal. Calcd for C22H16N2OS: C, 74.13; H, 4.52; N, 
7.86; S, 8.99. Found: C, 73.83; H, 4.54; N, 7.89; S, 
8.95%. 
 
Synthesis of 4-([1,1ʹ-biphenyl]-4-yl)-6-(2-hydroxy 
phenyl)pyrimidin-2-ol, 3bʹ 
The compund 3bʹ was realized from the reaction of 
1 (1.0 g, 0.003 mol) with urea (0.2 g, 0.003 mol)  
by succeeding the usual method as affirmed formerly 
for 3aʹ. 
3bʹ: Yield 0.8 g (72%), yellow solid, m.p.  
122-124°C. IR (KBr): 3402 (C2ʹ-OH), 3378 (C2-OH), 
3038 (aromatic C-H) and 1597 cm−1 (C=N); 1H NMR 
(400 MHz, DMSO-d6): δ 12.04 (1H, brs, C2ʹ-OH), 
9.83 (1H, brs, C2-OH), 7.91 (2H, d, Jo = 7.3 Hz, H-2ʹʹ, 
6ʹʹ), 7.71 (4H, m, H-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 7.65 (1H, s, H-5), 
7.48 (3H, m, H-3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ), 7.42 (1H, d, Jo = 7.9 Hz, 
H-5ʹ), 7.31 (1H, dd, Jm,o = 2.3, 7.0 Hz, H-6ʹ), 7.01 
(2H, d, Jo = 7.3 Hz, H-3ʹ, 4ʹ); 13C NMR (100 MHz, 
DMSO-d6): δ 166.59 (C-2), 163.41 (C-4), 160.95  
(C-6), 158.47 (C-2ʹ), 145.32 (C-1ʹʹ), 139.27 (C-4ʹʹ, 
1ʹʹʹ), 130.21 (C-1ʹ), 129.99 (C-2ʹʹ, 6ʹʹ), 129.05 (C-3ʹʹ, 
5ʹʹ), 128.71 (C-2ʹʹʹ, 6ʹʹʹ), 127.87 (C-3ʹʹʹ, 5ʹʹʹ), 126.97 
(C-5ʹ), 126.83 (C-4ʹʹʹ), 125.49 (C-6ʹ), 120.27 (C-4ʹ), 
113.77 (C-3ʹ), 106.96 (C-5); ESI-MS: m/z 363 
(M+Na, 35%), 341 (M+1, 85%). Anal. Calcd for 
C22H16N2O2: C, 77.63; H, 4.74; N, 8.23. Found: C, 
77.94; H, 4.72; N, 8.26%. 
 
Synthesis of 2-(6-([1,1ʹ-biphenyl]-4-yl)-2-
aminopyrimidin-4-yl)phenol, 3cʹ 
The heterocycle 3cʹ was synthesized through the 
condensation reaction of 1 (1.0 g, 0.003 mol) with 
guanidine hydrochloride (0.3 g, 0.003 mol) by 
applying the above demonstrated procedure. 
3cʹ: Yield 0.85 (78%), yellow solid, m.p.  
106-108°C. IR (KBr): 3412 (O-H), 3379, 3305 (N-H), 
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3044 (aromatic C-H), and 1592 cm−1 (C=N); 1H NMR 
(400 MHz, DMSO-d6): δ 9.81 (1H, brs, OH), 8.40 
(2H, brs, NH2), 7.90 (1H, s, H-5), 7.86 (2H, d, Jo = 7.5 
Hz, H-2ʹʹ, 6ʹʹ), 7.76 (4H, m, H-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 7.46 
(3H, m, H-3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ), 7.40 (1H, d, Jo = 7.1 Hz,  
H-5ʹ), 7.33 (1H, dd, Jm,o = 2.5, 7.7 Hz, H-6ʹ), 6.96 
(2H, d, Jo = 8.0 Hz, H-3ʹ, 4ʹ); 13C NMR (100 MHz, 
DMSO-d6): δ 165.18 (C-2), 164.55 (C-4), 161.78  
(C-6), 157.89 (C-2ʹ), 144.27 (C-1ʹʹ), 137.76 (C-4ʹʹ, 
1ʹʹʹ), 131.28 (C-1ʹ), 130.39 (C-2ʹʹ, 6ʹʹ), 129.90 (C-3ʹʹ, 
5ʹʹ), 128.58 (C-2ʹʹʹ, 6ʹʹʹ), 127.88 (C-3ʹʹʹ, 5ʹʹʹ), 127.15 
(C-5ʹ), 126.97 (C-4ʹʹʹ), 124.42 (C-6ʹ), 118.51 (C-4ʹ), 
115.34 (C-3ʹ), 108.05 (C-5); ESI-MS: m/z 340 (M+1, 
16%), 339 (M+, 100%) . Anal. Calcd for C22H17N3O: 
C, 77.86; H, 5.05; N, 12.38. Found: C, 78.17; H, 5.07; 
N, 12.42%. 
 
Synthesis of 2-(2-([1,1ʹ-biphenyl]-4-yl)-1H-benzo 
[b][1,4]diazepin-4-yl)phenol, 4aʹʹ 
A mixture of compound 1 (1.0 g, 0.003 mol), o-
phenylenediamine (0.4 g, 0.003 mol), KOH (0.3 g, 
0.006 mol) and absolute ethanol (25.0 mL) was 
refluxed vigorously for 8 h. Upon the completion of 
reaction, the excess solvent was distilled off under 
reduced pressure and residue mass was poured  
into crushed ice to afford a crude substance  
which was cyrstallized with EtOH to yield a pure 
benzodiazepine 4aʹʹ. 
4aʹʹ: Yield 0.95 (79%), brown solid, m.p.  
128-130°C. IR (KBr): 3480 (N-H), 3214 (O-H), 3083 
(aromatic C-H) and 1593 cm−1 (C=N); 1H NMR (400 
MHz, DMSO-d6): δ 9.72 (1H, brs, OH), 8.71 (1H, brs, 
NH), 8.08 (4H, t, Jo = 8.1 Hz, H-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 7.93 
(2H, d, Jo = 8.0 Hz, H-2ʹʹ, 6ʹʹ), 7.81 (2H, d, Jo = 8.2 
Hz, H-3ʹʹʹ, 5ʹʹʹ), 7.76 (2H, dd, Jm,o = 2.2, 7.9 Hz H-5ʹ, 6ʹ), 
7.55 (1H, dd, Jp,o = 1.0, 8.0 Hz H-10), 7.51 (2H, t,  
Jo = 8.4 Hz, H-8, 9), 7.41 (1H, t, Jo = 7.6 Hz, H-7), 
7.16 (1H, dd, Jm,o = 2.5, 7.8 Hz, H-4ʹʹʹ), 7.00 (1H, td, 
Jm,o = 2.7, 8.0 Hz, H-4ʹ), 6.58 (1H, d, Jo = 7.6 Hz,  
H-3ʹ), 5.25 (IH, s, H-3); 13C NMR (100 MHz, DMSO-d6): 
δ 164.15 (C-2), 155.73 (C-2ʹ), 150.01 (C-6), 144.01 
(C-11), 142.30 (C-4), 139.33 (C-1ʹʹ), 135.69 (C-4ʹʹ, 
1ʹʹʹ), 135.14 (C-1ʹ), 129.14 (C-2ʹʹ, 6ʹʹ), 129.02 (C-3ʹʹ, 
5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 127.94 (C-3ʹʹʹ, 5ʹʹʹ), 127.61 (C-5ʹ), 126.88 
(C-4ʹʹʹ), 126.77 (C-8, 9), 120.81 (C-6ʹ),  
116.93 (C-7, 10), 116.12 (C-4ʹ), 114.67 (C-3ʹ), 90.37 
(C-3); ESI-MS: m/z 411 (M+Na, 29%), 390 (M+2, 
60%), 389 (M+1, 90%). Anal. Calcd for C27H20N2O: 
C, 83.48; H, 5.19; N, 7.21. Found: C, 83.81; H,  
5.16; N, 7.23%. 
Synthesis of 2-(2-([1,1ʹ-biphenyl]-4-yl)benzo[b] 
[1,4]oxazepin-4-yl)phenol, 4bʹʹ 
The reaction of 1 (1.0 g, 0.003 mol) with 2-
aminophenol (0.3 g, 0.003 mol) under the similar 
reactions conditions as explained above for 4a” 
afforded the new product 4bʹʹ. 
4bʹʹ: Yield 0.96 g (74%), brown solid, m.p. 142-
144°C. IR (KBr): 3268 (O-H), 3074 (aromatic C-H) 
and 1589 cm−1 (C=N); 1H NMR (400 MHz,  
DMSO-d6): δ 9.64 (1H, brs, OH), 8.01 (2H, d, Jo = 7.8 
Hz, H-2ʹʹ, 6ʹʹ), 7.96 (4H, m, H-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 7.89 
(3H, t, Jo = 7.3 Hz, H-3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ), 7.72 (1H, d,  
Jo = 8.0 Hz H-5ʹ), 7.61 (2H, d, Jo = 7.4 Hz, H-8, 9), 
7.55 (1H, td, Jm,o = 2.1, 7.6 Hz, H-6ʹ), 7.18 (2H, dd, 
Jm,o = 2.6, 7.0 Hz, H-7, 10), 7.04 (1H, t, Jo = 8.2 Hz H-
4ʹ), 6.99 (1H, m, H-3ʹ), 5.51 (IH, s, H-3); 13C NMR 
(100 MHz, DMSO-d6): δ 164.68 (C-2), 157.75 (C-2ʹ), 
151.98 (C-6), 143.35 (C-11), 142.17 (C-4), 139.58 
(C-1ʹʹ), 136.41 (C-4ʹʹ, 1ʹʹʹ), 134.72 (C-1ʹ), 130.88  
(C-2ʹʹ, 6ʹʹ), 129.95 (C-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 128.64 (C-3ʹʹʹ, 
5ʹʹʹ), 127.33 (C-5ʹ), 126.99 (C-4ʹʹʹ), 126.02 (C-8, 9), 
119.21 (C-6ʹ), 117.76 (C-7, 10), 116.54 (C-4ʹ), 114.39 
(C-3ʹ), 93.74 (C-3); ESI-MS: m/z 390 (M+1, 90%), 
389 (M+, 32%). Anal. Calcd for C27H19NO2: C, 83.27; 
H, 4.92; N, 3.60. Found: C, 83.60; H, 4.94; N, 3.58%. 
 
Synthesis of 2-(2-([1,1ʹ-biphenyl]-4-yl)benzo[b] 
[1,4]thiazepin-4-yl)phenol, 4cʹʹ 
The heterocycle 4cʹʹ was obtained by the reaction 
of 1 (1.0 g, 0.003 mol) and 2-aminothiophenol (0.4g, 
0.003 mol) using the similar process as prescribed 
earlier for 4aʹʹ. 
4cʹʹ: Yield 0.89 g (68%), brown solid, m.p. 198-
200°C. IR (KBr): 3257 (O-H), 3025 (aromatic C-H) 
and 1600 cm−1 (C=N); 1H NMR (400 MHz, DMSO-
d6): δ 9.68 (1H, brs, OH), 8.16 (4H, d, Jo = 8.1 Hz, H-
3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 8.09 (2H, d, Jo = 8.0 Hz, H-2ʹʹ, 6ʹʹ), 
7.91 (2H, d, Jo = 7.9 Hz, H-3ʹʹ ,ʹ 5ʹʹ )ʹ, 7.72 (2H, d, Jo = 8.1 Hz, 
H-8, 9), 7.65 (2H, d, Jo = 7.9 Hz, H-7, 10), 7.50 (3H, 
m, H-5ʹ, 6ʹ, 4ʹʹʹ), 7.39 (2H, t, Jo = 7.3 Hz, H-3ʹ, 4ʹ), 
6.33 (IH, s, H-3); 13C NMR (100 MHz, DMSO-d6): δ 
164.35 (C-2), 158.61 (C-2ʹ), 152.43  
(C-6), 145.08 (C-11), 143.88 (C-4), 140.22 (C-1ʹʹ), 
136.50 (C-4ʹʹ, 1ʹʹʹ), 135.26 (C-1ʹ), 131.19 (C-2ʹʹ, 6ʹʹ), 
130.66 (C-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 129.45 (C-3ʹʹʹ, 5ʹʹʹ), 128.76 
(C-5ʹ), 127.77 (C-4ʹʹʹ), 126.90 (C-8, 9), 122.19 (C-6ʹ), 
118.65 (C-7, 10), 117.32 (C-4ʹ), 115.51 (C-3ʹ), 99.15 
(C-3); ESI-MS: m/z 407 (M+2, 65%), 406 (M+1, 
13%), 405 (M+, 88%). Anal. Calcd for C27H19NOS: C, 
79.97; H, 4.72; N, 3.45. Found: C, 79.65; H, 4.74;  
N, 3.46%. 
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Synthesis of (R)-2-(5-([1,1ʹ-biphenyl]-4-yl)-4,5-
dihydroisoxazol-3-yl)phenol, 5 
A solution of compound 1 (1.0 g, 0.003 mol), 
hydroxylamine hydrochloride (0.2 g, 0.003 mol), 
KOH (0.3 g, 0.006 mol) and dry EtOH (25.0 mL) was 
refluxed for 6 h. After the completion of reaction 
(inspected from TLC), the resulting mixture was 
added slowly into ice cold hydrochloric acid to 
acquire a solid product which were filtered off, 
washed with water and dried. The crude product was 
crystallized by using MeOH as a solvent to yield a 
pure product 5. 
5: Yield 0.74 g (70%), light brown solid, m.p.  
154-156°C. IR (KBr): 3260 (O-H), 3073 (aromatic  
C-H), 2924 (aliphatic C-H) and 1600 cm−1 (C=N); 
1H NMR (400 MHz, CDCl3): δ 9.72 (1H, brs, OH), 
7.53 (4H, dd, Jm,o = 2.8, 8.0 Hz, H-3ʹʹ, 5ʹʹ, 2ʹʹʹ, 6ʹʹʹ), 
7.42 (3H, t, Jo = 7.2 Hz, H-3ʹʹʹ, 4ʹʹʹ, 5ʹʹʹ), 7.33 (4H, m, 
H-5ʹ, 6ʹ, 2ʹʹ, 6ʹʹ), 7.28 (1H, m, H-3ʹ), 6.90 (1H, dt,  
Jm,o = 2.1, 7.3 Hz, H-4ʹ), 5.62 (1H, dd, JXA = 4.6 Hz,  
JXM= 11.5 Hz, HX), 3.75 (1H, dd, JMX = 11.5 Hz, 
 JMA = 17.2 Hz, HM), 3.18 (1H, dd, JAX = 4.6 Hz,  
JAM = 17.2 Hz, HA); 13C NMR (100 MHz, DMSO-d6): 
δ 157.52 (C-2ʹ), 154.25 (C-3), 141.56 (C-1ʹʹ), 139.83 
(C-4ʹʹ), 139.17(C-1ʹʹʹ), 132.27 (C-1ʹ), 129.87 (C-2ʹʹ, 
6ʹʹ), 128.90 (C-3ʹʹ, 5ʹʹ)127.38 (C-2ʹʹʹ, 6ʹʹʹ), 127.00  
(C-3ʹʹʹ, 5ʹʹʹ), 126.59 (C-5ʹ), 126.09 (C-4ʹʹʹ), 117.81  
(C-6ʹ), 117.58 (C-4ʹ), 112.74 (C-3ʹ), 60.13 (C-5), 
42.05 (C-4); ESI-MS: m/z 317 (M+2, 13%), 316 (M+1, 
54%), 315 (M+, 100%). Anal. Calcd for C21H17NO2: C, 
79.98; H, 5.43; N, 4.44. Found: C, 80.29; H, 5.45; N, 
4.42%. 
 
Conclusion 
The present research work represents a general and 
efficient method for the synthesis of varied rings new 
heterocyclic products (pyrazolines, isoxazoline, 
pyrimidines and benzoazepines) under the very 
simple conditions without using any expensive and 
toxic reagents. One intermediate chalcone has been 
straightforwardly transformed into various heterocycles 
by using suitable cyclizing agents. Among the newly 
prepared heterocycles, pyrazolines and isoxazoline 
revealed the noticeable antimicrobial properties. 
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